Accelerated Community Oncology Research Network
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Accelerated Community Oncology Research Network sits in the top decile of US sponsors by registered trial count (#886 of 15,742 sponsors by registered trial count).
Accelerated Community Oncology Research Network: 16 sponsored US clinical trials, none currently recruiting.
Accelerated Community Oncology Research Network sponsors 16 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 10 completed. 1 of these trials are in Phase 3-4 (later-stage) and 15 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Primary Peritoneal Carcinoma, with 1 trials.
Top-decile sponsor footprint
Accelerated Community Oncology Research Network ranks in the top decile of sponsors by registered trial count (#886 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
10 of 16 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (62.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
16 total, page 1 of 1
Panitumumab, Paclitaxel, Carboplatin and 5FU in the Treatment of Potentially Resectable Gastroesophageal Adenocarcinoma
NCT01182610
Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
NCT00924352
Phase 2b Study of Cetuximab With Platinum-Based Chemo as First Line Treatment of Recurrent or Advanced NSCLC
NCT00828841
A Phase I Trial Evaluating mFOLFOX6 and Avastin With Nexavar as First-Line Treatment for Metastatic Colorectal Cancer
NCT00779311
Randomized Study of Sorafenib Dose Escalation in Patients With Previously Untreated Metastatic Renal Cell Carcinoma
NCT00557830
Phase II Trial of Capecitabine With Fulvestrant for Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer
NCT00534417
Phase II Study Alimta and Gemzar + Avastin as First Line Chemotherapy for Elderly Patients With Stage IIIB/IV NSCLC
NCT00517595
1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy
NCT00493636
Mitoxantrone, Prednisone Plus Sorafenib in Taxane-Refractory Metastatic Hormone Refractory Prostate Cancer (HRPC)
NCT00452387
Bevacizumab With Abraxane in Patients With Recurrent Ovarian/ Peritoneal Cancer
NCT00407563
Oral Topotecan to Treat Recurrent or Persistent Solid Tumors
NCT00382733
Treating Chronic Insomnia in Breast Cancer Patients
NCT00337272
Alternative Schedule of Velcade/Dexamethasone Plus Doxil for Patients With Multiple Myeloma
NCT00366106
Phase I, Dosage-finding and PK Study of IV Topotecan and Erlotinib With Refractory Solid Tumors
NCT00611468
Study of Gamma Interfereon in Metastatic Colorectal Carcinoma
NCT00786643
Neoadjuvant Chemotherapy + Herceptin in HER2 Positive Stage II-III Breast Cancer Patients
NCT00270894
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 11 |
| Phase 4 | 1 |
Therapeutic Areas
How the Accelerated Community Oncology Research Network early-phase archive is shaped
16 indexed studies, none listed as recruiting (0% open); 10 completed (63%).
Phase mix: 1 late (III/IV) vs 15 early (I/II) (early-phase heavy).
Top condition: Primary Peritoneal Carcinoma (1 trial), 2 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Accelerated Community Oncology Research Network: archived-pipeline peers nationwide
Peers matched on 16 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Accelerated Community Oncology Research Network sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 16 archived trials
- Altimmune · 16 trials · 6% recruiting
- American University · 16 trials · 13% recruiting
- Anthera Pharmaceuticals · 16 trials · 0% recruiting
- A.T. Still University of Health Sciences · 16 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Accelerated Community Oncology Research Network page
16 registered trials is a research-attention snapshot, not an endorsement of Accelerated Community Oncology Research Network or any single study.
- None of Accelerated Community Oncology Research Network's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Primary Peritoneal Carcinoma is the condition Accelerated Community Oncology Research Network studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Primary Peritoneal Carcinoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Accelerated Community Oncology Research Network pipeline card: 16 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.